What does innovative medicine — acquisition related costs mean?

These are the costs directly attributable to the acquisition of businesses or assets within the Innovative Medicine segment, including transaction fees, integration costs, and professional services. This metric highlights the financial impact of inorganic growth strategies on the segment's bottom line.

Johnson & Johnson (JNJ) Innovative Medicine — Acquisition related costs

Screener

Similar metrics at other companies

RNGRReportable Segment — Acquisition related costs

$400K+100%

RNGRWireline Services — Acquisition related costs

$300K+50.0%

SITMReportable Segment — Acquisition related costs

$8.51M+355%

RNGRHigh Specification Rigs — Acquisition related costs

$500K—

RNGRProcessing Solutions and Ancillary Services — Acquisition related costs

-$300K—

AMRXAffordable Medicines — Acquisition costs

$0—

Other financials

Income statement

See full

Revenue$25.3B+6.6%

Gross profit$17.3B+7.1%

Operating income$7.1B+7.4%

Net income$5.5B-0.1%

EPS (diluted)$2.27-0.9%

Balance sheet

See full

Cash & equivalents$20.4B+9.9%

Total debt$49.0B-3.4%

Total equity$85.0B+8.3%

Total assets$201.06B+4.0%

Cash flow

See full

Operating cash flow$8.6B+122%

CapEx$1.3B+26.7%

Free cash flow$7.3B+157%

Valuation

See full

Market cap$619.3B+50.7%

Enterprise value$647.91B+46.2%

P/E29.4×+11.3×

P/S6.3×+1.8×

Profitability

See full

Gross margin67.9%0.0pp

Operating margin26.5%+2.8pp

Net margin21.5%-3.5pp

FCF margin22.7%+2.2pp

Returns & leverage

See full

Return on equity25.7%-4.5pp

Debt / equity0.6×-0.1×

Current ratio1.1×+0.1×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.

The source filing: Johnson & Johnson’s 10-Q, filed July 23, 2026.

Filed: Jul 23, 2026, 4:04 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000200406-26-000153

Restructuring related charge of $0.2 billion in both the fiscal second quarter and fiscal six months of 2026. Refer to Note 12 for additional details.
Acquisition and integration related expense of $0.1 billion in both the fiscal second quarter of 2026 and fiscal six months of 2026 and $0.2 billion in both the fiscal second quarter of 2025 and fiscal six months of 2025, primarily related to the Intra-Cellular acquisition.

Item 1 — Financial statements

FAQ

What is Johnson & Johnson's innovative medicine — acquisition related costs?: Johnson & Johnson (JNJ) reported innovative medicine — acquisition related costs of $100M in Q2 2026.
How has Johnson & Johnson's innovative medicine — acquisition related costs changed year-over-year?: Johnson & Johnson's innovative medicine — acquisition related costs decreased by 50.0% year-over-year, from $200M to $100M.
What does innovative medicine — acquisition related costs mean?: These are the costs directly attributable to the acquisition of businesses or assets within the Innovative Medicine segment, including transaction fees, integration costs, and professional services. This metric highlights the financial impact of inorganic growth strategies on the segment's bottom line.